The U.S. Food and Drug Administration has agreed to give priority review status to Johnson & Johnson’s application for a new usage of its prostate cancer treatment Zytiga, Reuters reports. That means the drug will be reviewed faster than usual.
The priority review status is granted by the FDA to expedite the review of drugs to treat serious diseases and fill unmet medical needs. It means the drug will be reviewed ...
continue reading...